GSDMB and cancer: This targeted nanomedicine (termed AbGB-NCs) increased the sensitivity to trastuzumab in vitro, but also reduced cancer cell migration as well as in vivo breast tumor growth and lung metastasis in orthotopic xenografts, specifically in GSDMB-overexpressing cells, without systemic toxicity [45].